-
Rosuvastatin calcium (Crestor) just passed its one-year anniversary since being approved by the U.S. Food and Drug Administration (FDA). Although by reports it has generated almost $4 billion in annual sales for AstraZeneca, the approval initially brought mixed feelings for many physicians, says Peter H. Jones, MD.
-
Now that the National Cholesterol Education Program has updated its clinical practice guidelines on cholesterol management, one of the questions is how health care providers can reach the lower treatment goals for low-density lipoprotein (LDL) cholesterol for patients at high and moderately high risk of a heart attack.
-
Pentetate calcium trisodium injection (Ca-DTPA) and pentetate zinc trisodium injection (Zn-DTPA) by Hameln Pharmaceuticals, GmbH, of Hameln, Germany.
-
Patients warned of clinical differences in thyroid meds; Higher costs affect MS patients adherence to medications; FDA issues warnings, label changes; Survey highlights importance of pharmacist/patient relationship.
-
Many elderly Americans still are being prescribed potentially inappropriate medications, according to a study published in the Aug. 9/23 issue of the Archives of Internal Medicine.
-
Some physicians advocate early, aggressive therapy to help reduce low-density lipoprotein (LDL) cholesterol levels. One new study, however, indicates that patients treated with high-dose simvastatin (Zocor) did not show a significant reduction in the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, readmission for acute coronary syndrome (ACS), and stroke.
-
The National Cholesterol Education Program, a product of a collaboration of the National Heart, Lung, and Blood Institutes, the American College of Cardiology, and the American Heart Association, has updated its clinical practice guideline on cholesterol management.
-
-
The hundreds of presentations at this meeting provided encouraging evidence that existing Alzheimers therapies may have greater benefits than first realized, and that a new generation of potential disease-modifying therapies for AD may be on the way.
-
It seems prudent to strongly consider use of melatonin in our cognitively delayed patients with disordered sleep, but to monitor those with epilepsy very closely for exacerbation, and withdraw the drug.
